Richard L. Gieseck

Richard L. Gieseck

Auto-generated profile, based on publicly available information

Richard L. Gieseck

Immunopathogenesis Section, Laboratory of Parasitic Diseases, NIAID, NIH, Bethesda, MD, USA

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 August 2017 in Nature Reviews Immunology
Verified
Journal Article
Closed access
PDF file
RGRichard L. Gieseck
Richard L. Gieseck
MWMark S. Wilson
Mark S. Wilson
TWThomas A. Wynn
Thomas A. Wynn

19 August 2015 in Science Translational Medicine
Verified
Journal Article
Open access
PDF file
DCDavid F. Choy
David F. Choy
KHKevin M. Hart
Kevin M. Hart
LBLee Borthwick
Lee Borthwick
ASAarti Shikotra
Aarti Shikotra
DNDeepti R. Nagarkar
Deepti R. Nagarkar
PBPeter Bradding
Peter Bradding
Increasing evidence suggests that asthma is a heterogeneous disorder regulated by distinct molecular mechanisms. In a cross-sectional study of asthmatics of varying severity (n = 51), endobronchial tissue gene expression analysis revealed three major patient clusters: TH2-high, TH17-high, and TH2/17-low. TH2-high and TH17-high patterns were mutually exclusive in individual patient samples, and their gene signatures were inversely correlated and differentially regulated by interleukin-13 (IL-13) and IL-17A. To understand this dichotomous pattern of T helper 2 (TH2) and TH17 signatures, we investigated the potential of type 2 cytokine suppression in promoting TH17 responses in a preclinical model of allergen-induced asthma. Neutralization of IL-4 and/or IL-13 resulted in increased TH17 cells and neutrophilic inflammation in the lung. However, neutralization of IL-13 and IL-17 protected mice from eosinophilia, mucus hyperplasia, and airway hyperreactivity and abolished the neutrophilic inflammation, suggesting that combination therapies targeting both pathways may maximize therapeutic efficacy across a patient population comprising both TH2 and TH17 endotypes.

3 July 2017 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
FSFotios Sampaziotis
Fotios Sampaziotis
AJAlexander W Justin
Alexander W Justin
OTOlivia C Tysoe
Olivia C Tysoe
SSStephen Sawiak
Stephen Sawiak
EGEdmund M Godfrey
Edmund M Godfrey
LVLudovic Vallier
Ludovic Vallier

22 January 2014 in PLOS ONE
Verified
Journal Article
Open access
PDF file
RIRichard L. Gieseck Iii
Richard L. Gieseck Iii
NHNicholas RF Hannan
Nicholas RF Hannan
RBRoque Bort
Roque Bort
NHNeil A. Hanley
Neil A. Hanley
RDRosemary A. L. Drake
Rosemary A. L. Drake
LVLudovic Vallier
Ludovic Vallier
Induced pluripotent stem cell derived hepatocytes (IPSC-Heps) have the potential to reduce the demand for a dwindling number of primary cells used in applications ranging from therapeutic cell infusions to in vitro toxicology studies. However, current differentiation protocols and culture methods produce cells with reduced functionality and fetal-like properties compared to adult hepatocytes. We report a culture method for the maturation of IPSC-Heps using 3-Dimensional (3D) collagen matrices compatible with high throughput screening. This culture method significantly increases functional maturation of IPSC-Heps towards an adult phenotype when compared to conventional 2D systems. Additionally, this approach spontaneously results in the presence of polarized structures necessary for drug metabolism and improves functional longevity to over 75 days. Overall, this research reveals a method to shift the phenotype of existing IPSC-Heps towards primary adult hepatocytes allowing such cells to be a more relevant replacement for the current primary standard.

28 June 2017 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
KHKevin M. Hart
Kevin M. Hart
TFThomas Fabre
Thomas Fabre
JSJoshua C. Sciurba
Joshua C. Sciurba
RGRichard L. Gieseck
Richard L. Gieseck
LBLee A. Borthwick
Lee A. Borthwick
TWThomas A. Wynn
Thomas A. Wynn
Development of NASH fibrosis is accompanied by accumulation of hepatic eosinophils and driven by TGF-β and profibrotic type 2 inflammation.

1 July 2016 in Immunity
Verified
Journal Article
Closed access
RGRichard L. Gieseck
Richard L. Gieseck
TRThirumalai R. Ramalingam
Thirumalai R. Ramalingam
KHKevin M. Hart
Kevin M. Hart
KVKevin M. Vannella
Kevin M. Vannella
DCDavid A. Cantu
David A. Cantu
TWThomas A. Wynn
Thomas A. Wynn